• 1
    Yamada A, Sayegh MH. The CD154, CD40 costimulatory pathway in transplantation. Transplantation 2002; 73: S36S39.
  • 2
    Li Y, Li XC, Zheng XX, Wells A, Turka LA, Strom TB. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nature Med 1999; 5: 12981302.
  • 3
    Wekerle T, Sayegh MH, Hill J et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998; 187: 20372044.
  • 4
    Wekerle T, Kurtz J, Ito H et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nature Med 2000; 6: 464469.
  • 5
    Durham M, Bingaman A, Adams A et al. Administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165: 14.
  • 6
    Seung E, Iwakoshi N, Woda BA et al. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: Absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood 2000; 95: 21752182.
  • 7
    Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001; 14: 417424.
  • 8
    Tomita Y, Khan A, Sykes M. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a non-myeloablative regimen. J Immunol 1994; 153: 10871098.
  • 9
    Khan A, Tomita Y, Sykes M. Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen. Transplantation 1996; 62: 380387.
  • 10
    Manilay JO, Pearson DA, Sergio JJ, Swenson KG, Sykes M. Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a non-myeloablative conditioning regimen. Transplantation 1998; 66: 96102.
  • 11
    Kubo RT, Born W, Kappler JW, Marrack P, Pigeon M. Characterization of a monoclonal antibody which detects all murine alpha-beta T cell receptors. J Immunol 1989; 142: 27362742.
  • 12
    Tan P, Anasetti C, Hansen JA et al. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Medical 1993; 177: 165173.
  • 13
    Sayegh MH, Akalin E, Hancock WW et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Medl 1995; 181: 18691874.
  • 14
    Honey K, Cobbold SP, Waldmann H. CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. J Immunol 1999; 163: 48054810.
  • 15
    Wells A, Li XC, Li Y et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nature Medical 1999; 5: 13031307.
  • 16
    Wekerle T, Sayegh MH, Chandraker A, Swenson KG, Zhao Y, Sykes M. Role of peripheral clonal deletion in tolerance induction with bone marrow transplantation and costimulatory blockade. Transplant Proc 1999; 31: 680.
  • 17
    Wekerle T, Kurtz J, Sayegh MH et al. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol 2001; 166: 23112316.
  • 18
    Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998; 280: 243248.
  • 19
    Iwakoshi NN, Mordes JP, Markees TG, Phillips NE, Rossini AA, Greiner DL. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol 2000; 164: 512521.
  • 20
    Li W, Lu L, Wang L, Fung JJ, Thomson AW, Qian S. Costimulation blockade promotes the apoptotic death of graft-infiltrating T cells and prolongs survival of hepatic allografts from FLT3L-treated donors. Transplantation 2001; 72: 14231432.
  • 21
    Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434438.
  • 22
    Kirk AD, Burkly LC, Batty DS et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nature Med 1999; 5: 686693.
  • 23
    Ito H, Kurtz J, Shaffer J, Sykes M. CD4 cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40–CD40L interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway. J Immunol 2001; 166: 29702981.
  • 24
    Kurtz J, Ito H, Wekerle T, Shaffer J, Sykes M. Mechanisms involved in the establishment of tolerance through costimulatory blockade and BMT. Lack of requirement for CD40L-mediated signaling for tolerance or deletion of donor-reactive CD4+ cells. Am J Transplant 2001; 1: 339349.
  • 25
    Sykes M, Romick ML, Hoyles KA, Sachs DH. In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment. J Exp Med 1990; 171: 645658.
  • 26
    Tomita Y, Sachs DH, Khan A, Sykes M. Additional mAb injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mAbs and 3 Gy whole body irradiation. Transplantation 1996; 61: 469477.
  • 27
    Unkeless JC. Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors. J Exp Med 1979; 150: 580596.
  • 28
    Sykes M, Szot GL, Swenson K, Pearson DA. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nature Med 1997; 3: 783787.
  • 29
    Acha-Orbea H, Palmer E. Mls: a retrovirus exploits the immune system. Immunol Today 1991; 12: 356361.
  • 30
    Dyson PJ, Knight AM, Fairchild S, Simpson E, Tomonari K. Genes encoding ligands for deletion of Vβ11 T cells cosegregate with mammary tumour virus genomes. Nature 1991; 349: 531532.
  • 31
    Bill J, Kanagawa O, Woodland D, Palmer E. The MHC molecule I-E is necessary but not sufficient for the clonal deletion of VB11 bearing T cells. J Exp Med 1989; 169: 14051419.
  • 32
    Tomonari K, Fairchild S. The genetic basis of negative selection of Tcrb-V11+ T cells. Immunogenetics 1991; 33: 157162.
  • 33
    Tomita Y, Sachs DH, Sykes M. Myelosuppressive conditioning is required to achieve engraftment of pluripotent stem cells contained in moderate doses of syngeneic bone marrow. Blood 1994; 83: 939948.
  • 34
    Kneitz B, Herrmann T, Yonehara S, Schimpl A. Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in IL-2-deficient mice. Eur J Immunol 1995; 25: 25722577.
  • 35
    Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 1991; 353: 858861.
  • 36
    Refaeli Y, Parise LV, London C, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 1998; 8: 615623.
  • 37
    Grillot D, Merino R, Nunez G.Bcl-xL displays restricted distribution during T cell development and inhibits multiple forms of apoptosis but not clonal deletion in transgenic mice. J Exp Med 1995; 182: 19731983.
  • 38
    Salomon B, Bluestone JA Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001; 19: 225252.
  • 39
    Shi YF, Sahai BM, Green DR. Cyclosporin A inhibits activation-induced death in T-cell hybridoma and thymocytes. Nature 1989; 339: 625626.
  • 40
    Yazdanbakhsh K, Choi J, Li Y, Lau L, Choi Y. Cyclosporin A blocks apoptosis by inhibiting the DNA binding activity of the transcription factor Nur77. Proc Natl Acad Sci U S A 1995; 92: 437441.
  • 41
    Schreiber S, Crabtree G. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136142.
  • 42
    Blaha P, Bigenzahn S, Koporc Z et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulatory blockade. Blood 2003; 101: 28862893.
  • 43
    Taylor PA, Lees CJ, Wilson JM et al. The combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood 2002; 100: 34003407.
  • 44
    Russell JH. Activation-induced death of mature T cells in the regulation of immune responses. Curr Opin Immunol 1995; 7: 382388.
  • 45
    Van Parijs L, Ibraghimov A, Abbas AK. The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity 1996; 4: 321328.
  • 46
    Van Parijs L, Biuckians A, Abbas AK. Functional roles of Fas and Bcl-2-regulated apoptosis of T lymphocytes. J Immunol 1998; 160: 20652071.
  • 47
    Li XC, Strom TB, Turka LA, Wells A. T cell death and transplantation tolerance. Immunity 2001; 14: 407416.
  • 48
    Honey K, Bemelman F, Cobbold S, Waldmann H. High dose bone marrow transplantation induces deletion of antigen-specific T cells in a Fas-independent manner. Transplantation 2000; 69: 16761682.
  • 49
    Laouar Y, Sarukhan A, Pasqualetto V, Garcia C, Ezine S. Involvement of the Fas (CD95) system in peripheral cell death and lymphoid organ development. Eur J Immunol 1998; 28: 10781088.
  • 50
    Koenen HJ, Joosten I. Blockade of CD86 and CD40 induces alloantigen-specific immunregulatory T cells that remain anergic even after reversal of hyporesponsiveness. Blood 2000; 95: 31533161.
  • 51
    Taylor PA, Noelle RJ, Blazar BR. CD4+CD25+ immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001; 193: 13111318.